Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

AAPG

Ascentage Pharma Group International ADR

May 01 • 04:00PM ET

23.34

+0.47 2.03 %

Healthcare • Biotechnology • China • Mid • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.94	Insider Own	-	Shs Outstand	52.23M	Perf Week	-2.55%
Market Cap	2.17B	Forward P/E	-	EPS next Y	-0.51	Insider Trans	-	Shs Float	-	Perf Month	-11.19%
Enterprise Value	2.10B	PEG	-	EPS next Q	-0.58	Inst Own	0.05%	Short Float	-	Perf Quarter	-3.47%
Income	-172.95M	P/S	27.07	EPS this Y	48.42%	Inst Trans	1.42%	Short Ratio	0.24	Perf Half Y	-30.12%
Sales	80.00M	P/B	11.45	EPS next Y	51.51%	ROA	-37.25%	Short Interest	0.00M	Perf YTD	-11.05%
Book/sh	2.04	P/C	6.13	EPS next 5Y	49.56%	ROE	-153.24%	52W High	48.45 -51.83%	Perf Year	-7.20%
Cash/sh	3.81	P/FCF	-	EPS past 3/5Y	0.80% -1.32%	ROIC	-58.06%	52W Low	19.11 22.14%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	36.88% 113.42%	Gross Margin	79.17%	Volatility	1.70% 1.92%	Perf 5Y	-
Dividend TTM	-	EV/Sales	26.22	EPS Y/Y TTM	-159.09%	Oper. Margin	-210.95%	ATR (14)	0.95	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.77	Sales Y/Y TTM	-41.19%	Profit Margin	-216.20%	RSI (14)	44.64	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.79	EPS Q/Q	-	SMA20	-7.34%	Beta	0.18	Target Price	47.00
Payout	-	Debt/Eq	1.50	Sales Q/Q	-	SMA50	-3.86%	Rel Volume	0.30	Prev Close	22.88
Employees	767	LT Debt/Eq	0.57	Earnings	Mar 24 AMC	SMA200	-26.80%	Avg Volume	3.05K	Price	23.34
IPO	Jan 27, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	21.69% 11.46%	Trades		Volume	914	Change	2.03%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-24-26	Initiated	Deutsche Bank	Buy	$40
Mar-12-26	Resumed	BTIG Research	Buy	$48
Jan-13-26	Initiated	Rodman & Renshaw	Buy	$48
Dec-04-25	Initiated	Oppenheimer	Outperform	$45
Nov-24-25	Initiated	Truist	Buy
Nov-10-25	Initiated	BTIG Research	Buy	$50
Nov-05-25	Initiated	Piper Sandler	Overweight	$48
Mar-27-25	Initiated	JP Morgan	Overweight

Apr-21-26 08:00PM	Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026 (GlobeNewswire)
Apr-19-26 08:00PM	Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting (GlobeNewswire)
Mar-25-26 07:00PM	Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates (GlobeNewswire)
Mar-17-26 08:00PM	Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026 (GlobeNewswire)
Mar-11-26 08:00AM	Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026 (GlobeNewswire)
08:00AM	Loading…
Feb-23-26 08:00AM	Ascentage Pharma to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Feb-11-26 03:16PM	Rodman & Renshaw Initiates Ascentage Pharma Group International (AAPG) with Buy Rating, $48 Target (Insider Monkey)
Feb-09-26 08:00AM	Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Feb-06-26 06:13PM	Ascentage Pharma Receives Clearance from Chinas CDE for New Drug (Exec Edge)
Feb-05-26 06:30PM	Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 (GlobeNewswire)
Jan-14-26 08:25PM	Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
12:10AM	Ascentage: Partnership With Takeda Going Well (Bloomberg)
Jan-07-26 05:09PM	Ascentage Pharma B-Cell Cancer Candidate Receives FDA IND Clearance (Exec Edge) +8.50%
Jan-06-26 08:00PM	Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288 (GlobeNewswire)
Dec-17-25 08:00AM	Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
07:45PM	Loading…
Dec-08-25 07:45PM	ASH 2025 Updated Data for Ascentage Pharma's Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment (GlobeNewswire)
07:45PM	ASH 2025 Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP (GlobeNewswire)
07:45PM	ASH 2025 Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60% (GlobeNewswire)
Dec-07-25 08:10PM	ASH 2025 Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Exposed Patients with Myeloid Malignances (GlobeNewswire)
Dec-06-25 10:15AM	Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-04-25 07:00PM	Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA (GlobeNewswire) +7.10%
07:27AM	An Arch-backed biotech raises $53M to fight neurodegeneration (BioPharma Dive)
Dec-01-25 08:00AM	Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025 (GlobeNewswire)
Nov-24-25 07:00PM	Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature's Signal Transduction and Targeted Therapy (GlobeNewswire)
Nov-19-25 08:00AM	Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025 (GlobeNewswire)
Nov-05-25 09:51AM	Pinterest downgraded, Tractor Supply upgraded: Wall Street's top analyst calls (The Fly)
Nov-03-25 08:10PM	Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025 (GlobeNewswire)
08:10PM	Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025 (GlobeNewswire)
Oct-29-25 08:00PM	Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025 (GlobeNewswire)
Oct-07-25 08:00AM	Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025 (GlobeNewswire)
12:00PM	Loading…
Sep-01-25 12:00PM	Ascentage Pharma Group International - Unsponsored ADR (AAPG) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:55AM	Here's Why Ascentage Pharma Group International - Unsponsored ADR (AAPG) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Aug-25-25 08:00AM	Ascentage Pharma to Participate in Three Upcoming Investor Conferences in September 2025 (GlobeNewswire) -9.23%
Aug-20-25 07:57PM	Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates (GlobeNewswire)
Aug-19-25 04:20PM	Ascentage Pharmas Lisaftoclax Gets FDA/EMA Clearance (Exec Edge)
Aug-17-25 07:30PM	Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA (GlobeNewswire)
Aug-07-25 08:00AM	Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025 (GlobeNewswire)
Aug-01-25 08:00AM	Ascentage Pharma to Participate in Evercore China Biotech Summit (GlobeNewswire)
Jul-23-25 08:00AM	Ascentage Pharma to Participate in BTIG Virtual Biotechnology Conference 2025 (GlobeNewswire)
Jul-21-25 12:14AM	Ascentage Pharma Raises $192.3M Through Oversubscribed Offshore Share Placement (Insider Monkey)
Jul-17-25 04:30AM	Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement (GlobeNewswire)
Jul-14-25 11:12AM	Ascentage Pharma's Novel Cancer Drug Approved in China (Insider Monkey) -5.33%
10:35AM	Ascentage Pharma Announces Pricing of Top-Up Placement (GlobeNewswire)
05:23AM	Ascentage Pharma Announces Proposed Top-Up Placement (GlobeNewswire)
Jul-10-25 12:55PM	Ascentage Pharma Announces NMPA Approval for Blood Cancer Drug (Exec Edge)
09:30AM	Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL (GlobeNewswire)
Jul-08-25 11:58AM	Ascentage Pharma Names CFO & SVP of Global Corporate Development & Finance (Exec Edge)
Jul-07-25 07:30PM	Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance (GlobeNewswire)
Jun-15-25 07:30PM	EHA 2025 Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL (GlobeNewswire)
Jun-09-25 07:30PM	Thirteen Studies of Ascentage Pharma's Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress (GlobeNewswire) +5.29%
Jun-02-25 07:30PM	Live from ASCO 2025 Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors (GlobeNewswire) +10.03%
07:30PM	Live from ASCO 2025 Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report (GlobeNewswire)
May-22-25 08:15PM	Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025 (GlobeNewswire)
May-11-25 05:20PM	Is Ascentage Pharma (AAPG) the Best Performing Healthcare Stock to Buy Now? (Insider Monkey)
Apr-28-25 07:00AM	Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax (GlobeNewswire)
Apr-23-25 07:00PM	Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin (GlobeNewswire) +10.65% +6.69%
Apr-21-25 06:10PM	Ascentage Pharma Drugs Included in Chinese Society of Clinical Oncology Guidelines (Exec Edge) +12.97%
07:00AM	Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines (GlobeNewswire)
Apr-02-25 01:07PM	Stocks To Watch In Gloomy Market Including This Breakout IPO (Investor's Business Daily)
Mar-27-25 07:00AM	Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates (GlobeNewswire) +9.96%
Mar-25-25 07:00PM	Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire)
Mar-12-25 08:46AM	Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025 (GlobeNewswire)
Mar-06-25 05:18PM	Ascentage Secures Third Breakthrough Therapy for Ph+ ALL Treatment (Exec Edge)
Mar-05-25 06:00PM	Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) (GlobeNewswire)
Feb-07-25 08:24AM	Ascentage Pharma Announces Partial Exercise of Underwriters' Option to Purchase Additional American Depositary Shares (GlobeNewswire)
Jan-28-25 04:01PM	Ascentage Pharma Announces Closing of U.S. Initial Public Offering (GlobeNewswire)

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AAPG

Ascentage Pharma Group International ADR

Upgrade your Finviz experience